Interleukin 17 (IL-17) promotes the expression of chemokines and cytokines via the induction of gene transcription and post-transcriptional stabilization of mRNA. We show here that IL-17 enhanced the stability of chemokine CXCL1 mRNA and other mRNAs through a pathway that involved the adaptor Act1, the adaptors TRAF2 or TRAF5 and the splicing factor SF2 (also known as alternative splicing factor (ASF)). TRAF2 and TRAF5 were necessary for IL-17 to signal the stabilization of CXCL1 mRNA. Furthermore, IL-17 promoted the formation of complexes of TRAF5-TRAF2, Act1 and SF2 (ASF). Overexpression of SF2 (ASF) shortened the half-life of CXCL1 mRNA, whereas depletion of SF2 (ASF) prolonged it. SF2 (ASF) bound chemokine mRNA in unstimulated cells, whereas the SF2 (ASF)-mRNA interaction was much lower after stimulation with IL-17. Our findings define an IL-17-induced signaling pathway that links to the stabilization of selected mRNA species through Act1, TRAF2-TRAF5 and the RNA-binding protein SF2 (ASF).
Interleukin 17A (IL-17A) is a proinflammatory cytokine produced mainly by CD4 + T cells of the T H 17 helper T cell subset that are distinct from the classical T helper type 1 (T H 1) and T H 2 cells 1,2 . Although IL-17 is required for host defense against bacterial and fungal infection, it is also known for its role in the pathogenesis of certain human and animal autoimmune inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease and experimental autoimmune encephalomyelitis [1] [2] [3] . IL-17 coordinates tissue inflammation through higher expression of proinflammatory cytokines and chemokines, which collectively determine the magnitude and character of the response.
Among the earliest responses to injury is the expression of genes encoding chemokines in cell populations resident in the injured tissue, whose products specifically regulate the trafficking of neutrophils 4, 5 . These endogenously derived peptides contribute to many features of chemotactic recruitment; thus, their regulation is of paramount importance 6 . Neutrophil-specific chemokines are members of the CXC family (CXCL1-CXCL8 in humans, and CXCL1, CXCL2 and CXCL5 in mice), contain the ELR motif (glutamic acid, leucine and arginine) and act through the receptors CXCR1 and CXCR2. IL-17 is well documented to promote high expression of CXCL1 and related chemokines in fibroblasts and epithelial cell populations [7] [8] [9] and is known to signal at least in part through activation of the transcription factor NF-κB via the adaptors Act1 and TRAF6 (refs. 10-13) . Although increases in transcription driven by NF-κB are a requisite feature of the induced expression of CXCL1, regulation of the half-life of the mRNA is also a critical determinant of the magnitude of expression 14, 15 . Those mRNAs that are highly unstable prevent inappropriate expression of the encoded protein in resting cells but often require stimulus-induced prolongation of their half-life during inflammatory stimulation. Notably, the mechanisms through which IL-17 promotes enhanced mRNA stability in nonmyeloid cell populations seem to be distinct from those that operate downstream of Toll-like receptors in myeloid cells 16, 17 .
The main paradigm for the instability of mRNAs encoding cytokines, chemokines and growth factors involves adenine-and uridine-rich regions in the 3′ untranslated region (UTR) of the message that are recognized by proteins that function to orchestrate the sequential deadenylation, decapping and, ultimately, exonucleolytic degradation of the RNA 18, 19 . Among the best studied of these sequence motifs is the core pentamer AUUUA, which is often flanked by additional adenine or uridine residues. Many proteins with recognition specificity for this motif have been identified and shown to have the ability to either promote or diminish the rate of mRNA degradation. These include the ELAV family member HuR, AUF1 (hnRNP D), tristetraprolin and the splicing-regulatory factor KSRP 19 . Although the role of such RNA-binding proteins in regulating the half-life of mRNA is well recognized, the diversity of factors and the signal-transduction pathways downstream of extracellular stimuli that modulate their activities remain poorly defined.
Here we identify an mRNA stability-signaling pathway that coupled to the IL-17 receptor (IL-17R) via the downstream signaling intermediate Act1. After stimulation with IL-17, Act1 formed a complex with TRAF5 (or TRAF2), and both TRAF proteins were required for IL-17-mediated stabilization of CXCL1 mRNA. IL-17 also induced association of the RNA-splicing-regulatory factor SF2 (ASF) with the A r t i c l e s complex of Act1 and TRAF5-TRAF2. SF2 (ASF) promoted chemokine mRNA instability in a sequence-specific way, and depletion of SF2 (ASF) resulted in prolonged mRNA half-life. SF2 (ASF) bound chemokine mRNA in unstimulated cells, but the SF2 (ASF)-mRNA interaction was much lower after stimulation with IL-17. Our findings define a separate IL-17-initiated signaling pathway linked to the stabilization of a subset of mRNAs in nonmyeloid cell populations.
RESULTS
TRAF2 and TRAF5 promote enhanced stability of CXCL1 mRNA TRAF6 is essential for the ability of IL-17 to activate target-gene transcription via NF-κB 11, 12 , yet it is not required to promote prolongation of the half-life of CXCL1 mRNA 16 . To assess the roles of other members of the TRAF family, we used an experimental system of reporter plasmids in which transgene transcription is controlled by a tetracycline-responsive element through the action of the tetracycline transactivator protein. We transfected HeLa human cervical cancer cells stably expressing tetracycline transactivator protein with a reporter construct (KC∆4) containing the region encoding CXCL1 and a truncated 3′ UTR that confers instability that can be attenuated after stimulation with IL-17 (ref. 17) . In HeLa Tet-Off cells (in which transcription is inactive in the presence of tetracycline or doxycycline) transfected with this construct, we readily detected the transcript, but after transcriptional blockade achieved by the addition of doxycyline, the message decayed rapidly with a half-life of 25-50 min. IL-17 provided at the same time as doxycyline extended the halflife to 2-3 h (Fig. 1a) . In cells cotransfected with the reporter and expression plasmid encoding TRAF2 or TRAF5, the message was also stabilized (Fig. 1b) , which suggested that TRAF2 and TRAF5 each have the ability to mediate the stability of CXCL1 mRNA. As reported before 16 , we did not obtain similar results with cells transfected to express TRAF6 (Fig. 1b) . The ability of TRAF5 to stabilize mRNA was relatively selective for the CXCL1 3′ UTR sequence motif, as the half-life of another unstable reporter containing the 3′ UTR of mRNA encoding the myeloid growth factor GM-CSF was not altered in cells overexpressing TRAF5 (Fig. 1c) . These findings suggest that TRAF2 or TRAF5 serves to couple IL-17R signals to control of the half-life of chemokine mRNA.
IL-17-induced CXCL1 mRNA stability requires TRAF2 and TRAF5 To further test the hypothesis that TRAF2 or TRAF5 may be important an component of IL-17 signaling that leads to selective mRNA stabilization, we evaluated the ability of IL-17 to promote enhanced stability of CXCL1 mRNA in mouse embryo fibroblasts (MEFs) deficient in both TRAF2 and TRAF5. In many nonmyeloid cells, including MEFs, tumor necrosis factor (TNF) is a potent transcriptional stimulus for the gene encoding CXCL1 but is unable to promote message stability 9, 20 . This enables comparison of the half-life of mRNA in cells with or without the addition of a stabilizing stimulus such as IL-17. In wild-type MEFs, treatment for 2 h with TNF resulted in endogenous CXCL1 mRNA transcripts that decayed rapidly after addition of the transcriptional inhibitor actinomycin D (Fig. 2a) . In cells stimulated with TNF and IL-17 in combination (IL-17 alone is a poor transcriptional stimulus for CXCL1), the half-life of the induced CXCL1 mRNA was prolonged considerably (Fig. 2a) . IL-17 was unable to stabilize CXCL1 mRNA in MEFs deficient in both TRAF2 and TRAF5. Sensitivity for IL-17-driven stabilization of mRNA was restored by reconstitution of those double-knockout cells with both TRAF2 and TRAF5 (Fig. 2b) . Other IL-17-sensitive mRNAs, including those encoding colony-stimulating factor 3 (CSF3) and the NF-κB regulator IκBζ, also showed similar activity in cells deficient in both TRAF2 and TRAF5 (Supplementary Fig. 1a ). When we assessed MEFs from mice singly deficient in either TRAF2 or TRAF5 in this experiment, we found no change in IL-17-induced stabilization of mRNA (data not shown).
We also assessed the requirement for TRAF2 and/or TRAF5 in cytokine-induced stabilization of mRNA with the HeLa Tet-Off system by abrogating the expression of either or both factors through the use of specific small interfering RNA (siRNA). Transfection of siRNA targeting TRAF2 or TRAF5 resulted in lower abundance of these proteins than that in cultures treated with nonspecific control siRNA (Fig. 2c) . The half-life of KC∆4 mRNA was similar in both untreated and control siRNA-treated cells, and treatment with IL-17 resulted in the message stabilization similar to that reported above (Fig. 1) . As in MEFs with single knockout of TRAF2 or TRAF5, the half-life of reporter mRNA was unchanged in cultures treated with siRNA targeting TRAF2 or TRAF5, and sensitivity to IL-17 was retained. However, IL-17-induced stabilization of KC∆4 mRNA was much lower in cells treated with siRNA targeting both TRAF2 and TRAF5 (Fig. 2c) . These results provide evidence that either TRAF2 or TRAF5 (or both) is (are) required for IL-17 to prolong the half-life of chemokine mRNA.
Dominant-interfering TRAF5 blocks mRNA stability
The observation that deficiency in both TRAF2 and TRAF5 was necessary to abolish the ability of IL-17 to stabilize CXCL1 mRNA indicated functional redundancy of TRAF2 and TRAF5 in this pathway. We then determined whether mutants of TRAF2, TRAF5 or TRAF6 able to block cytokine-induced activation of NF-κB via dominant-negative activity could also inhibit IL-17 signaling to stabilize mRNA. In HeLa Tet-Off cells cotransfected with the KC∆4 reporter transgene and empty expression vector (pcDNA3), IL-17 promoted enhanced stability of the message. Overexpression of dominant-negative versions of TRAF2 or TRAF6 had little effect on the cytokine-induced prolongation of half-life, despite effectively blocking IL-1-stimulated NF-κB activity, as assessed with a κB-dependent luciferase reporter ( Supplementary Fig. 2 and data not shown). Overexpression of the dominant-negative TRAF5 construct, however, blocked mRNA stabilization induced by IL-17. These findings suggest that TRAF5 may have a selective role in this signaling pathway.
IL-17 induces interaction between Act1 and TRAF5
TRAF2 and TRAF5 are best known for participating in signaling by members of the TNF receptor superfamily 21 . The requirement for TRAF2 or TRAF5 in IL-17-induced mRNA stability suggested that one or both might interact with Act1, the adaptor that is essential for most IL-17 responses 9,11 . We transfected HeLa Tet-Off cells with a hemagglutinin-tagged version of Act1 and Flag-tagged versions of TRAF2, TRAF5 or TRAF6 and immunoprecipitated proteins from detergent extracts with a Flag-specific antibody. We subsequently separated the immunoprecipitates by SDS-PAGE and analyzed them by immunoblot with antibody to hemagglutinin (anti-hemagglutinin; Fig. 3a) . Hemagglutinin-tagged Act1 was readily detectable among the proteins immunoprecipitated with anti-Flag in cells expressing any of the three Flag-tagged TRAF proteins but not in cells transfected with empty vector. Because the evidence favored a predominant role for TRAF5, we focused on this member of the TRAF family in our remaining experiments. In cells expressing Act1 and TRAF5 via transgenes, we did not find IL-17 dependency for the Act1-TRAF5 interaction (data not shown). Therefore, we assessed the stimulus dependence of the interaction between endogenous Act1 and TRAF5 in untransfected HeLa cells left untreated or treated with IL-17. We immunoprecipitated proteins from cell lysates with anti-TRAF5, then separated immunoprecipitates by denaturing SDS-PAGE and analyzed them by immunoblot with anti-Act1. Although we did not detect Act1 in samples immunoprecipitated with nonspecific immunoglobulin G (IgG) or in untreated cells, we readily observed it among proteins immunoprecipitated with anti-TRAF5 from cells treated for 5, 15 or 30 min with IL-17 ( Fig. 3b) . We observed many bands interactive with anti-TRAF5, one of which reproducibly showed dependence on IL-17 stimulation. Although TRAF5 that migrated to a position of the expected molecular mass was present in all lanes, the IL-17-induced form migrated to a position indicative of much greater mass (approximately 85 kDa). Finally, we immunoprecipitated proteins from IL-17-treated MEFs with anti-Act1 and analyzed the immunoprecipitates by immunoblot with anti-TRAF5. Several Act1-interacting, anti-TRAF5-reactive bands were dependent on IL-17 stimulation (Fig. 3c) . These bands migrated more slowly than did unmodified TRAF5 but migrated to positions similar to those of the proteins immunoprecipitated with anti-TRAF5, which suggested that interaction of TRAF5 with Act1 may lead to some form of molecular modification. Act1 has been shown to have ubiquitin E3 ligase activity 22 , which raises the possibility that the forms of higher molecular mass might represent a ubiquitinated form of TRAF5.
IL-17 induces interaction among Act1, TRAF5 and SF2 (ASF)
To extend the understanding of signals downstream of IL-17R, Act1 and TRAF5, we searched for TRAF5-interacting molecules that could provide a link between TRAF5 and the mRNA-decay pathways. We obtained detergent extracts of untreated or IL-17-treated MEFs deficient in both TRAF2 and TRAF5 that were reconstituted with Flag-tagged TRAF2 and TRAF5, immunoprecipitated proteins from the cells with anti-Flag, then separated the immunoprecipitates by SDS-PAGE, followed by silver staining. We identified a band whose migration was indicative of a mass of approximately 35 kDa that seemed to associate with the TRAF proteins only in cells treated A r t i c l e s with IL-17 ( Fig. 4a) . We treated that band to in-gel digestion with trypsin and liquid chromatography-mass spectrometry, then analyzed the results with a search engine that uses such data to identify proteins from sequence databases (in this case, the nonredundant rodent Reference Sequence database of the National Center for Biotechnology Information); it was identified as the arginine-and serine-rich splicing factor SRSF1 (also known as SF2 (ASF)). We assessed the ability of TRAF5 to interact with SF2 (ASF) in extracts of HeLa cells left untreated or treated for 5, 15, or 30 min with IL-17, followed by immunoprecipitation with anti-TRAF5. Immunoblot analysis of immunoprecipitates separated by SDS-PAGE and probed with anti-SF2 identified a specific interaction that was dependent on stimulation with IL-17 and was present within 5 min (Fig. 4b) .
We demonstrated the specificity of the interaction with SF2 (ASF) through the use of transiently expressed Flag-tagged versions of TRAF2, TRAF4, TRAF5 and TRAF6. We observed SF2 (ASF) only among proteins immunoprecipitated with anti-TRAF2 or anti-TRAF5; it was absent from samples immunoprecipitated with anti-Flag from cells expressing Flag-tagged TRAF4 or TRAF6 (Fig. 4c) . In contrast, TAK1, a kinase involved in NF-κB activation that is known to interact strongly with TRAF6 (ref. 23) , did not interact with TRAF5 (Fig. 4d) . Thus, different TRAF proteins seem to function as segregation points for coupling with distinct downstream endpoints. To determine if the TRAF5-SF2 (ASF) complex contained Act1, we stimulated HeLa cells for up to 60 min with IL-17 and immunoprecipitated proteins from cell extracts with anti-Act1. The immunoprecipitates from this experiment contained both TRAF5 and SF2 (ASF) in addition to Act1 (Fig. 4e) , which suggested that all three proteins are assembled in this initial signaling complex.
SF2 (ASF) modulates specific mRNA half-lives
The finding that the interaction of SF2 (ASF) with TRAF5 was IL-17 dependent and the coincidence of that event with the stimulusinduced stabilization of chemokine mRNA suggested that SF2 (ASF) has some role in controlling the half-life of mRNA, consistent with several published studies 24, 25 . To assess the function of SF2 (ASF) in regulating the half-life of CXCL1 mRNA, we first examined the consequences of modulating the abundance of SF2 (ASF) by overexpression or by siRNA-mediated knockdown. In HeLa Tet-Off cells cotransfected with an expression plasmid encoding SF2 (ASF) along with the KC∆4 reporter, the steady-state abundance of KC∆4 mRNA was lower and its half-life was 50% that in cells transfected with empty vector and the KC∆4 reporter (Fig. 5a ). This effect was sequence specific, as there was no change in the half-life of a second unstable reporter containing the 3′ UTR of GM-CSF mRNA. That reporter was not sensitive to IL-17-mediated stabilization in HeLa cells (data not shown). IL-17 is known to enhance expression of CSF3 mRNA and IκBζ mRNA 1, 17 .
The half-lives of reporter mRNAs containing the 3′ UTRs from IκBζ mRNA and CSF3 mRNA were also prolonged in response to IL-17 in HeLa Tet-Off cells and shorter in cells cotransfected with the Fig. 1b,c) . We depleted HeLa Tet-Off cells of SF2 (ASF) by transfecting the cells with SF2 (ASF)-specific siRNA (Fig. 5b) . Although the half-life of KC∆4 mRNA was prolonged in cells depleted of SF2 (ASF), the decay of a second reporter containing an IL-17-insensitive region from CXCL1 mRNA (KC-Clu-P2) 17 was unaltered. Finally, we used MEFs that can be depleted of SF2 (ASF) expression by treatment with doxycycline 26 . When we treated these cells for 48 h with doxycycline, SF2 (ASF) expression was eliminated and the half-life of TNF-induced endogenous CXCL1 mRNA was prolonged (Fig. 5c) . Collectively, these results support the hypothesis that SF2 (ASF) promotes the decay of specific mRNAs depending on sequences located in the 3′ UTR.
IL-17 modulates the binding of SF2 (ASF) to target mRNA SF2 (ASF) is known to be localized mainly to the nucleus, and this subcellular distribution pattern is controlled in part via phosphorylation of multiple serine residues in the arginine-and serine-rich carboxyl (C)-terminal domain of the protein 27, 28 . We determined if an amino (N)-terminal region lacking the arginine-and serine-rich domain, which will localize more predominantly in the cytoplasm, was also able to mediate the effects on the decay of CXCL1 mRNA. Although transient expression of SF2 (ASF) with truncation of the C terminus modulated the half-life of the KC∆4 reporter as well as fulllength SF2 (ASF) did, SF2 (ASF) with truncation of the N terminus had no such activity (Fig. 6a) . We reasoned that the critical RNArecognition motif in the N-terminal domain of SF2 (ASF) was required for the RNA-decay-promoting activity. The modulation of the halflife of KC∆4-derived mRNA was lost in HeLa Tet-Off cells transfected with a mutant version of the SF2 (ASF) construct with deletion of the C terminus in which two phenylalanine residues critical for RNA binding (at positions 56 and 58) were substituted with aspartic acid 29 (Fig. 6b) .
As a further test of the functional linkage of SF2 (ASF) to the half-life of chemokine mRNA, we determined if SF2 (ASF) was able to bind CXCL1 mRNA and, if so, whether the interaction showed sequence specificity and/or stimulus dependency. For this, we prepared extracts of KC∆4-transfected HeLa Tet-Off cells as described before 17 and immunoprecipitated protein-bound mRNA from the A r t i c l e s extracts with anti-SF2 or with nonspecific mouse IgG. We used the immunoprecipitated pellets to prepare RNA, which we analyzed by real time RT-PCR for its abundance of CXCL1 reporter mRNA (relative to the abundance of GAPDH mRNA, encoding glyceraldehyde phosphate dehydrogenase). In cells transfected with KC∆4 reporter, transgene mRNA abundance in the samples immunoprecipitated with specific antibody was fourfold greater than that in samples immunoprecipitated with nonspecific IgG, as determined by the change in cycling threshold. In contrast, essentially no enrichment of reporter mRNA was obtained in cells transfected with the SF2 (ASF)-insensitive reporter KC-Clu-P2 (Fig. 6c) . In a second experiment we compared the immunoprecipitation-based enrichment for KC∆4 sequence in untreated and IL-17-treated cells. Consistent with our hypothesis, the interaction of SF2 (ASF) with the mRNA was much less in cells treated with IL-17. Finally, the RNA-binding mutant of SF2 (ASF) (with substitution of aspartic acid for phenylalanine residues critical for RNA binding) showed substantial loss of KC∆4-binding activity relative to that of SF2 (ASF) with a nonmutant N-terminal fragment. Collectively, these findings support the hypothesis that SF2 (ASF) is a mediator of the decay of selected mRNA species via specific RNA interaction and that this function is disrupted in response to IL-17 treatment, apparently as a consequence of interaction with TRAF5.
IL-17 uses TRAF5 and SF2 (ASF) in primary cells
The experiments reported above identified the role of TRAF2-TRAF5 and SF2 (ASF) in coupling IL-17 stimulation to mRNA stabilization in cell lines cultured for the long term. To evaluate the pathway in primary cells, we prepared cultures of kidney epithelial cells as described before 30 . Although TNF induced modest expression of CXCL1 mRNA in these cells, the combination of TNF plus IL-17 provided a very robust amplification due at least in part to the prolongation of mRNA half-life (Fig. 7a) . Several additional mRNA species encoding proinflammatory chemokines and cytokines, including CXCL2 (MIP-2), CCL2 (MCP-1) and CSF3, also showed enhanced half-life under the same treatment conditions (Fig. 7a) . IL-17 promoted the interaction of SF2 (ASF) with TRAF5 in primary kidney epithelial cells, as demonstrated by coimmunoprecipitation of SF2 (ASF) with anti-TRAF5 (Fig. 7b) . Finally, we evaluated the interaction of SF2 (ASF) with several IL-17-sensitive mRNAs by coimmunoprecipitation. Endogenous CXCL1 mRNA, CSF3 mRNA and CXCL2 (MIP-2) mRNA were each enriched in samples immunoprecipitated with anti-SF2 (ASF) relative to their abundance in samples immunoprecipitated with nonspecific immunoglobulin (Fig. 7c) . Furthermore, in each case, the interaction was disrupted by treatment with IL-17. Hence, IL-17 seems to use this pathway in primary mouse epithelial cells. DISCUSSION IL-17 acts together with TNF to induce expression of the gene encoding CXCL1 by stabilizing CXCL1 mRNA though a mechanism distinct from that used in myeloid cells simulated by Toll-like receptors 1, 9, 17 . Signaling downstream of IL-17R involves the adaptor Act1, which couples to activation of NF-κB via binding with TRAF6 (refs. 11,13,31) . However, TRAF6 is not required for IL-17-mediated stabilization of CXCL1 mRNA 16 . Collectively, such observations indicate that IL-17-mediated stabilization of CXCL1 mRNA involves a distinct signal-transduction pathway 32 . Here we found that IL-17 promoted interactions among Act1, TRAF2 or TRAF5, and the multifunctional RNA-splicing regulatory factor SF2 (ASF). SF2 (ASF) selectively enhanced the decay of target mRNA by binding to sites in 3′ UTRs, and this interaction was disrupted by IL-17, perhaps via TRAF5-dependent sequestration of limiting amounts of cytoplasmic SF2 (ASF).
The identification of TRAF5 and/or TRAF2 in signal transduction downstream of IL-17R is noteworthy. These TRAF proteins are known mainly for their roles in responses of members of the TNF receptor family, and their participation in IL-17-mediated modulation of the half-life of chemokine mRNA provides the first evidence to our knowledge of their participation in this signaling pathway. Notably, as in signaling by the TNF receptor family, these two proteins seem to provide redundant function in the IL-17 pathway, as mRNA stabilization was compromised only in cells doubly deficient in both 21, 33 . A dominant-negative version of TRAF5 was the most effective in blocking IL-17-mediated stabilization of mRNA, which suggests that TRAF5 is the more physiological regulator. The hypothesis that these TRAF proteins are involved in IL-17 response was supported by the ligand dependency of the interactions of TRAF2 or TRAF5 with both Act1 and SF2 (ASF). Indeed, all three proteins seemed to assemble in the initial signaling complex after receptor stimulation.
The selectivity of TRAF2 and TRAF5 for interaction with SF2 (ASF), in contrast to that of TRAF6 for TAK1, suggests the hypothesis that selective TRAF interaction provides an important segregation point in IL-17 signaling at which the upstream events can be independently coupled to distinct functional endpoints (that is, NF-κB versus mRNA stabilization). It is also noteworthy that the form of TRAF5 that interacted with Act1 in IL-17-stimulated cells migrated by SDS-PAGE with much greater mobility, which suggested that it had been subjected to post-translational modification. In this context, Act1 has been shown to have E3 ubiquitin ligase activity in its U-box domain 22 , and we speculate that TRAF5 may be subjected to modification through such activity. TRAF6 is also an E3 ubiquitin ligase, and this activity is critical for its function in promoting the activation of NF-κB 34, 35 , but neither TRAF2 or TRAF5 seems to have this activity 36 .
The initial identification of SF2 (ASF) as a candidate RNA-binding protein involved in the stability of chemokine mRNA was based on its ligand-dependent interaction with TRAF2 and TRAF5. Nevertheless, the finding that SF2 (ASF) had a substantial role in the control of specific mRNA decay was not unexpected given the considerable range of functions that have been attributed to this molecule 37, 38 . These include not only regulation of standard and alternative splicing but also nuclear-cytoplasmic transport 28 , the efficiency of message translation 24 , surveillance of mRNA quality (nonsense-mediated decay) 39 and sequence-specific mRNA decay 24, 25 . Relevant to that, manipulation of the expression of TRAF2, TRAF5 and SF2 (ASF) selectively affected the activity of mRNAs containing the IL-17-sensitive sequence motif in their 3′ UTRs 17, 40 . Notably, the ability of SF2 (ASF) to modulate the half-life of CXCL1 mRNA was dependent on sequence-selective RNA binding that was diminished by treatment with IL-17. As the interaction of SF2 (ASF) with TRAF2 or TRAF5 was dependent on the stimulus, the simplest hypothesis is that treatment with IL-17 results in the sequestration of SF2 (ASF). Although SF2 (ASF) is a very abundant protein, most SF2 (ASF) is located in the nucleus, so the sequestration of cytoplasmic forms may be effective in modulation of function. Whether the TRAF-SF2 (ASF) interaction has additional consequences beyond the effects on the half-life of chemokine and cytokine mRNA is unknown.
Our studies of CXCL1 mRNA instability identified two mechanisms distinguished by the 3′ UTR sequence motifs responsible for this and the proteins that bind such sequences and modulate the rate of decay 17, 41 . Although the paradigm of the control of the half-life of cytokine and chemokine mRNA dependent on adenine-and uridinerich regions via tristetraprolin is well established in myeloid cells 19, [42] [43] [44] , the pathway is not restricted to the myeloid lineage and indeed both the adenine-and uridine-rich region-tristetraprolin mechanism and the TRAF5-SF2 (ASF) mechanism may coexist in the same cell population 17 . It seems likely, however, that the SF2 (ASF) pathway for mRNA stabilization is not operative in myeloid cells, as CXCL1 mRNA is completely stable in tristetraprolin-deficient macrophages 41 . What is the rationale for the existence of multiple mechanisms that operate to control the stability of the same mRNA? The potential to have multiple regulatory sequence determinants, even in a single mRNA, enables cell type-and stimulus-specific response patterns similar to those of the regulatory sequences that govern inducible gene transcription. The fact that this TRAF5-SF2 (ASF) mechanism is observed mainly in nonmyeloid cell populations is noteworthy, as these cells are the more common target of the action of IL-17-driven recruitment of inflammatory neutrophils. Although the physiological importance of the IL-17-sensitive mechanism remains to be explored experimentally, it is probably important in IL-17-dependent pathogenesis, as mRNA stabilization seems to be necessary for the expression of CXC chemokines and the associated recruitment of inflammatory neutrophils.
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